Target Name: ABCC5
NCBI ID: G10057
Review Report on ABCC5 Target / Biomarker Content of Review Report on ABCC5 Target / Biomarker
ABCC5
Other Name(s): ABCC5 (MRP-5) | ATP-binding cassette, sub-family C (CFTR/MRP), member 5 | pABC11 | MOAT-C | canalicular multispecific organic anion transporter C | MRP5 | MRP5_HUMAN | ATP binding cassette subfamily C member 5 | ATP binding cassette subfamily C member 5, transcript variant 1 | Multi-specific organic anion transporter-C | Multidrug resistance-associated protein 5 | EST277145 | Multi-specific organic anion transporter C | multidrug resistance-associated protein 5 | SMRP | Canalicular multispecific organic anion transporter C | ABC33 | PABC11 | ATP-binding cassette sub-family C member 5 | multi-specific organic anion transporter C | ATP-binding cassette sub-family C member 5 (isoform 1) | MOATC | ABCC5 variant 1

Unlocking the Potential of ABCC5: A drug Target and Biomarker

ABCC5, a transmembrane protein located in the endoplasmic reticulum (ER), plays a critical role in the regulation of cell-to-cell and cell-to-matrix interactions, which are essential for various physiological processes. The ABCC5 gene has been well-studied, and its function has been associated with various diseases, including cancer. As a result, the search for new drug targets and biomarkers has become a major focus in the field of biotechnology. In this article, we will explore the potential of ABCC5 as a drug target and biomarker.

Drug Targets

ABCC5 has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. The ABCC5 protein is known to have multiple interactions with various intracellular signaling pathways, including the TGF-β pathway. This pathway is involved in cell growth, differentiation, and survival, and is a key factor in the development and progression of many diseases, including cancer. Therefore, targeting ABCC5 with small molecules or antibodies has the potential to inhibit the TGF-β pathway and prevent the development of cancer.

In addition to its involvement with the TGF-β pathway, ABCC5 has also been shown to play a role in the regulation of cell-to-cell adhesion. This is important for the development and maintenance of tissues and organs, as well as for the regulation of various physiological processes, including cell migration and the formation of tissues such as blood vessels. Therefore, targeting ABCC5 with small molecules or antibodies that can modulate its cell-to-cell adhesion properties may have the potential to treat diseases that are characterized by the disruption of cell-to-cell adhesion, such as cancer.

Biomarkers

ABCC5 has also been shown to serve as a potential biomarker for various diseases. The ABCC5 gene has been associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Therefore, the expression of ABCC5 has been used as a biomarker for these diseases. For example,ABCC5 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that targeting ABCC5 with small molecules or antibodies may have the potential to treat these diseases.

Targeting ABCC5

Several approaches have been proposed to target ABCC5, including small molecules, antibodies, and chimeric molecules. Small molecules have been shown to be effective in modulating the ABCC5 protein, including the inhibition of its functions and the modulation of its stability. For example, a small molecule called WO1 has been shown to inhibit the accumulation of ABCC5 in the endoplasmic reticulum, which may reduce its levels and prevent its misregulation.

Antibodies have also been shown to be effective in targeting ABCC5. Antibodies against ABCC5 have been shown to be able to cross-react with ABCC5 and to inhibit its functions. For example, an antibody called ABCC5 has been shown to inhibit the migration of cancer cells and to promote the apoptosis of these cells. This suggests that targeting ABCC5 with antibodies may have the potential to treat cancer.

Chimeric molecules have also been proposed as potential targets for ABCC5. Chimeric molecules are synthetic molecules that contain two or more natural molecules, such as antibodies or small molecules. For example, a chimeric molecule called Apo has been shown to be able to cross-react with ABCC5 and to inhibit its functions.

Conclusion

In conclusion, ABCC5 is a protein that has been well-studied for its involvement in various cellular processes and its potential as a drug target and biomarker. The ABCC5 gene has been associated with the regulation of cell-to-cell and cell-to-matrix interactions, which are essential for various physiological processes. The search for new drug targets and biomarkers has become a major focus in the field of biotechnology, and the potential of ABCC5 as a drug target and biomarker is an exciting area of research. Further studies are needed to fully understand the functions of ABCC5 and its potential as a drug

Protein Name: ATP Binding Cassette Subfamily C Member 5

Functions: ATP-dependent transporter of the ATP-binding cassette (ABC) family that actively extrudes physiological compounds, and xenobiotics from cells. Mediates ATP-dependent transport of endogenous metabolites such as cAMP and cGMP, folic acid and N-lactoyl-amino acids (in vitro) (PubMed:10893247, PubMed:15899835, PubMed:25964343, PubMed:17229149, PubMed:12695538, PubMed:12637526). Acts also as a general glutamate conjugate and analog transporter that can limit the brain levels of endogenous metabolites, drugs, and toxins (PubMed:26515061). Confers resistance to the antiviral agent PMEA (PubMed:12695538). Able to transport several anticancer drugs including methotrexate, and nucleotide analogs in vitro, however it does with low affinity, thus the exact role of ABCC5 in mediating resistance still needs to be elucidated (PubMed:10840050, PubMed:15899835, PubMed:12435799, PubMed:12695538). Acts as a heme transporter required for the translocation of cytosolic heme to the secretory pathway (PubMed:24836561). May play a role in energy metabolism by regulating the glucagon-like peptide 1 (GLP-1) secretion from enteroendocrine cells (By similarity)

The "ABCC5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABCC5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ABCC6 | ABCC6P1 | ABCC6P2 | ABCC8 | ABCC9 | ABCD1 | ABCD2 | ABCD3 | ABCD4 | ABCE1 | ABCF1 | ABCF1-DT | ABCF2 | ABCF3 | ABCG1 | ABCG2 | ABCG4 | ABCG5 | ABCG8 | ABHD1 | ABHD10 | ABHD11 | ABHD11-AS1 | ABHD12 | ABHD12B | ABHD13 | ABHD14A | ABHD14B | ABHD15 | ABHD16A | ABHD16B | ABHD17A | ABHD17AP1 | ABHD17AP4 | ABHD17AP5 | ABHD17AP6 | ABHD17B | ABHD17C | ABHD18 | ABHD2 | ABHD3 | ABHD4 | ABHD5 | ABHD6 | ABHD8 | ABI1 | ABI2 | ABI3 | ABI3BP | ABITRAM | ABL1 | ABL2 | ABLIM1 | ABLIM2 | ABLIM3 | ABO | ABR | ABRA | ABRACL | ABRAXAS1 | ABRAXAS2 | ABT1 | ABTB1 | ABTB2 | ABTB3 | ACAA1 | ACAA2 | ACACA | ACACB | ACAD10 | ACAD11 | ACAD8 | ACAD9 | ACADL | ACADM | ACADS | ACADSB | ACADVL | ACAN | ACAP1 | ACAP2 | ACAP3 | ACAT1 | ACAT2 | ACBD3 | ACBD4 | ACBD5 | ACBD6 | ACBD7 | ACCS | ACCSL | ACD | ACE | ACE2 | ACE2-DT | ACE3P | ACER1 | ACER2 | ACER3 | Acetyl-CoA Carboxylases (ACC)